Myo‐inositol vs D‐chiro‐inositol
Live birth · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
38 questions · 38 findings · 2 reviews
No studies found 10 · 26.3%GRADE not reported 12 · 31.6%Very low 13 · 34.2%Low 3 · 7.9%Moderate 0 · 0%High 0 · 0%
Myo‐inositol vs D‐chiro‐inositol
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with D‐chiro‐inositol (very low certainty).
1 finding from 1 review
- OR 1.3 [0.27, 6.2]1 study · 84 participantsVery low
Myo‐inositol vs D‐chiro‐inositol
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs D‐chiro‐inositol
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with D‐chiro‐inositol (very low certainty).
1 finding from 1 review
- OR 3.86 [1.25, 11.89]1 study · 84 participantsVery low
Myo‐inositol vs D‐chiro‐inositol
Ovulation · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)
Live birth · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes live birth compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
- OR 2.42 [0.75, 7.83]2 studies · 84 participantsVery low
Myo‐inositol vs antioxidant (melatonin)
Ovulation · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs metformin
Live birth · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs metformin
Adverse events · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs metformin
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with an insulin‐sensitising agent (metformin) (very low certainty).
1 finding from 1 review
- OR 1.91 [0.81, 4.49]1 study · 120 participantsVery low
Myo‐inositol vs metformin
Ovulation · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes ovulation compared with an insulin‐sensitising agent (metformin) (very low certainty).
1 finding from 1 review
- OR 1.86 [0.89, 3.87]1 study · 120 participantsVery low
Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
- OR 0.4 [0.19, 0.86]4 studies · 535 participantsVery low
Myo‐inositol vs clomiphene
Live birth · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes live birth compared with an ovulation induction agent (clomiphene) (very low certainty).
1 finding from 1 review
- OR 1.27 [0.48, 3.4]1 study · 75 participantsVery low
Myo‐inositol vs clomiphene
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs clomiphene
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ multiple pregnancy compared with an ovulation induction agent (clomiphene) (very low certainty).
1 finding from 1 review
- OR 0.21 [0.01, 4.43]1 study · 75 participantsVery low
Myo‐inositol vs clomiphene
Clinical pregnancy · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs clomiphene
Ovulation rate · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes ovulation rate compared with an ovulation induction agent (clomiphene) (very low certainty).
1 finding from 1 review
- OR 0.59 [0.2, 1.68]1 study · 75 participantsVery low
Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
Myo‐inositol showed no clear difference in adverse event ‐ multiple pregnancy compared with placebo, no/standard treatment (low certainty).
1 finding from 1 review
- OR 1.04 [0.63, 1.71]2 studies · 425 participantsLow
Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
- OR 1.27 [0.87, 1.85]4 studies · 535 participantsVery low
Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)
Ovulation · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found